FDA approves bosutinib for pediatric patients with chronic myelogenous
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
Related Articles
July 17, 2025: Meeting of the Oncologic Drugs Advisory Committee
July 17, 2025: Meeting of the Oncologic Drugs Advisory Committee
FDA approves neoadjuvant and adjuvant pembrolizumab for resectable loc
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c
FDA approves tafasitamab-cxix
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab.
Outbreak Investigation of Listeria monocytogenes: Chicken Fettuccine
Do not eat or serve recalled chicken fettuccine alfredo meals made by certain FreshRealm, Inc. facilities. FDA’s investigation is ongoing.
FDA Adds Warning About Serious Risk of Heat-Related Complications
The patch can increase body temperature and cause heat-related complications, resulting in hospitalization or even death in some cases
Medtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial Contamination
June 17, 2025—Medtech Products Inc., a Prestige Consumer Healthcare Inc. company (“Medtech” or “Company”), is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup…
FDA approves tafasitamab-cxix
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab.
FDA approves tafasitamab-cxix
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab.
FDA approves tafasitamab-cxix
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab.